News

Cell-based assay better at detecting MG-driving antibodies

A cell-based assay for detecting myasthenia gravis (MG)-causing antibodies in the blood results in greater diagnostic accuracy than two other antibody tests, according to data from a study in China. The cell-based assay (CBA) was superior to enzyme-linked immunoabsorbent assay (ELISA) and radioactivity radioimmunoprecipitation assay (RIPA) at detecting antibodies…

Pregnant women with MG at higher risk of complications: Review study

Pregnant women with myasthenia gravis (MG) are particularly susceptible to severe disease-related complications, usually caused by generalized muscle weakness, which can put the mother and child at risk, according to a recent review study. Newborns should also be monitored for symptoms of transient neonatal MG, a form of…

Thymectomy is effective in children, adolescents with MG: Study

A thymectomy, or surgical removal of the thymus gland, was effective for children and adolescents with myasthenia gravis (MG), as indicated by lower medication use and healthcare utilization after surgery, a study reports. Demographic characteristics like age, sex, ethnicity, insurance payer type, residential region, and the surgical approach…

MG linked to lower quality of life, more use of medical care

People with myasthenia gravis (MG) experience a lower health-related quality-of-life impact, face a higher medical burden, and require more assistance from caregivers compared with the general population, according to data pulled from two international studies. MG patients also were more likely to take sick leave from work and to…

KabaFusion selected by UCB to provide Rystiggo to gMG patients

The home infusion company KabaFusion has announced that UCB has tapped it as a limited U.S. distribution partner for Rystiggo (rozanolixizumab-noli), the first therapy approved for adults with the two most common subtypes of generalized myasthenia gravis (gMG). Following its June approval by the U.S. Food…